FDA
-
-
-
-
-
-
-
Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting
-
-
-
-
-
-
-
Celsion (CLSN) Announces Data Safety Monitoring Board Recommends to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1
-
-
-
-
-
-
-
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
-
-
-
-
-
-
-
Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress
-
-
-
-
-
-
-
Celsion (CLSN), Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine
-
322,137 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

